A Real-World Study Using Claims Data to Evaluate Possible Failure of Opioid Treatment Regimens Among Patients with Hip and/or Knee Osteoarthritis in the US
Authors Gandhi K, Wei W, Huang A, Wang L, Iyer R, Katz NP
Received 8 January 2020
Accepted for publication 10 April 2020
Published 8 June 2020 Volume 2020:12 Pages 285—297
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Xing Lin Feng
Kavita Gandhi,1 Wenhui Wei,2 Ahong Huang,3 Li Wang,3 Ravi Iyer,1 Nathaniel P Katz4,5
1Teva Pharmaceutical Industries, Frazer, PA, USA; 2Regeneron Pharmaceuticals, Tarrytown, NY, USA; 3STATinMED Research, Dallas, TX, USA; 4Analgesic Solutions, Wayland, MA, USA; 5Tufts University School of Medicine, Boston, MA, USA
Correspondence: Nathaniel P Katz
Analgesic Solutions, 321 Commonwealth Road, Ste 204, Wayland, MA 01778, USA
Tel +1 781 444-9605
Fax +1 973 553-8888
Background: Although opioids may be used in the management of pain in patients with osteoarthritis (OA), there is a dearth of real-world data characterizing opioid regimen failure in these patients.
Objective: Using claims data, this study explored measures that may be potentially indicative of opioid treatment failure and the association of such potential failure with health care resource utilization (HRU) and costs.
Patients and Methods: Using a national employer-sponsored insurance claims database covering the years 2011– 2016, this retrospective longitudinal study identified adults with hip/knee osteoarthritis who filled ≥ 1 opioid prescription (index event) and had continuous health plan enrollment 6 months pre- and ≥ 12 months post-index. Index opioid regimen intensity was defined in the 3-month post-index period by frequency, average daily dose, and duration of action. Possible index opioid regimen failure was defined as an increase in opioid regimen intensity, addition of a non-opioid pain medication, joint surgery, or opioid-abuse-related events. One-year follow-up HRU and costs were compared between those with possible treatment failure and those without.
Results: Among 271,512 OA patients (61.5% knee; 11.1% hip; 27.4% both), 34.9% met the definition of possible index opioid regimen failure within a year: increased regimen intensity (16.1%), joint surgery (14.0%), addition of non-opioid pain medication (11.4%), and opioid-abuse-related events (1.9%). Rates of possible failure generally increased with higher index regimen intensity. Compared with those who did not fail, those who potentially failed their index treatment regimen had significantly higher HRU (P< 0.001), and all-cause ($36,699 vs $15,114) and osteoarthritis-related costs ($17,298 vs $1,967) (both P< 0.0001).
Conclusion: Among OA patients treated with opioids, approximately one-third may fail their index opioid regimen within a year and incur significantly higher HRU and costs than those without. Further research is needed to validate these findings with clinical outcomes.
Keywords: osteoarthritis, pain, opioids, treatment failure, health care resource use, costs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]